Skip to content

Vertex Pharmaceuticals VRTX Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively at other companies

Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$426K+16.4%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$9K0.0%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$5K0.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$1.03M+2.1%
Sana Biotechnology logo
Sana BiotechnologySANA
$27K+17.4%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$5K+66.7%

Other financials

Income statement

See full
Revenue$3.0B+7.8%
Gross profit$2.6B+7.8%
Operating income$1.1B+80.6%
Net income$1.0B+59.6%
EPS (diluted)$4.02+61.4%

Balance sheet

See full
Cash & equivalents$5.5B+17.5%
Total debt$2.0B+20.5%
Total equity$19.4B+17.4%
Total assets$26.5B+15.8%

Cash flow

See full
Operating cash flow$1.4B+74.4%
CapEx$133.4M+228%
Free cash flow$1.3B+66.4%

Valuation

See full
Market cap$126.07B+17.7%
Enterprise value$122.55B+18.2%
P/E29.1×
P/S10.3×+0.9×

Profitability

See full
Gross margin86.2%+0.2pp
Operating margin38.3%
Net margin35.5%
FCF margin30.4%+20.2pp

Returns & leverage

See full
Return on equity24.2%
Debt / equity0.1×0.0×
Current ratio+0.4×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vertex Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vertex Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
Vertex Pharmaceuticals (VRTX) reported common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively of $2.5M in Q1 2026.
How has Vertex Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively changed year-over-year?
Vertex Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively decreased by 3.8% year-over-year, from $2.6M to $2.5M.
What is the long-term trend for Vertex Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
Over 5 years (2020 to 2025), Vertex Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively has grown at a -0.8% compound annual growth rate (CAGR), from $2.6M to $2.5M.
What does common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively mean?
This represents the par value of the common shares issued and outstanding. It is a foundational component of shareholders' equity and reflects the legal capital contributed by shareholders. While often small in dollar terms, it tracks the number of shares issued and the company's basic ownership structure.